Literature DB >> 21391133

Type D personality predicts poor medication adherence in myocardial infarction patients.

Lynn Williams1, Rory C O'Connor, Neil Grubb, Ronan O'Carroll.   

Abstract

Type D personality, the combination of negative affectivity (NA) and social inhibition (SI), is an emerging risk factor in cardiovascular disease. This study aimed to examine one possible behavioural mechanism to explain the link between Type D and ill-health. It was hypothesised that Type D personality would predict medication adherence in myocardial infarction (MI) patients. In a prospective study, 192 MI patients (54 females and 138 males) completed measures of Type D personality and provided demographic and medical information 1 week post-MI, and then 131 patients went on to complete a self-report measure of medication adherence 3 months post-MI. It was found that Type D personality predicts adherence to medication, after controlling for demographic and clinical risk factors. Critically, the constituent components of Type D, NA and SI, interact to predict medication adherence, after controlling for the effects of each component separately. Poor adherence to medication may represent one mechanism to explain why Type D cardiac patients experience poor clinical outcome, in comparison to non-Type D patients. Interventions, which target the self-management of medication, may be useful in these high-risk patients.
© 2011 Taylor & Francis

Entities:  

Mesh:

Year:  2011        PMID: 21391133     DOI: 10.1080/08870446.2010.488265

Source DB:  PubMed          Journal:  Psychol Health        ISSN: 0887-0446


  21 in total

Review 1.  Psychological Aspects of Cardiac Care and Rehabilitation: Time to Wake Up to Sleep?

Authors:  Jonathan Gallagher; Giulia Parenti; Frank Doyle
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

2.  Type D personality is not associated with coronary heart disease risk in a North American sample of retirement-aged adults.

Authors:  Noel C Larson; Steven D Barger; Sumner J Sydeman
Journal:  Int J Behav Med       Date:  2013-06

3.  Preoperative depression symptom severity and its impact on adherence to preoperative beta-blocker therapy.

Authors:  Robert B Schonberger; Jessica Feinleib; Natalie Holt; Feng Dai; Cynthia Brandt; Matthew M Burg
Journal:  J Cardiothorac Vasc Anesth       Date:  2014-09-26       Impact factor: 2.628

4.  Type D personality, self-efficacy, and medication adherence in patients with heart failure-A mediation analysis.

Authors:  Jia-Rong Wu; Eun Kyeung Song; Debra K Moser
Journal:  Heart Lung       Date:  2015-05-13       Impact factor: 2.210

5.  Impact of type D personality on adherence to oral appliance therapy for sleep-disordered breathing.

Authors:  M Dieltjens; O M Vanderveken; D Van den Bosch; K Wouters; J Denollet; J A Verbraecken; P H Van de Heyning; M J Braem
Journal:  Sleep Breath       Date:  2012-11-13       Impact factor: 2.816

6.  Type D personality is associated with social anxiety in the general population.

Authors:  Nina Kupper; Johan Denollet
Journal:  Int J Behav Med       Date:  2014-06

7.  Psychosocial phenotyping as a personalization strategy for chronic disease self-management interventions.

Authors:  Miyong T Kim; Kavita Radhakrishnan; Elizabeth M Heitkemper; Eunju Choi; Marissa Burgermaster
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

8.  Type D personality predicts poor medication adherence in patients with heart failure in the USA.

Authors:  Jia-Rong Wu; Debra K Moser
Journal:  Int J Behav Med       Date:  2014

Review 9.  How are depression and type D personality associated with outcomes in chronic heart failure patients?

Authors:  Jos Widdershoven; Dionne Kessing; Angélique Schiffer; Johan Denollet; Nina Kupper
Journal:  Curr Heart Fail Rep       Date:  2013-09

10.  The relationship between Type D personality, affective symptoms and hemoglobin levels in chronic heart failure.

Authors:  Nina Kupper; Aline J Pelle; Balázs M Szabó; Johan Denollet
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.